+91-8668442535

Multiple Drug Resistance Bacterial Infection Treatment Market By Vector (Critical, Medium, High), By Drug Class (Cephalosporin, Beta Lactam, Beta Lactamase Inhibitors, Oxazolidinone, Cyclic Lipopeptide, Glycolipopeptides ) - Growth, Share, Opportunities & Competitive Analysis, 2017 - 2025

This report on the global multiple drug resistance bacterial infection treatment market studies various vectors and drug classes. The rising prevalence of antimicrobial drug resistance and increasing demand for rapid diagnostic testing kits will propel the multiple drug resistance bacterial infection treatment market's growth. The limiting factors related to this market are the complex regulatory approvals for antibiotics, which vary according to country. A promising pipeline of novel antibiotics with more effective mechanisms of action to counteract drug resistance by microbes will result in deep market penetration of the multiple drug resistance bacterial infection treatment market.

For the purpose of this study, the vectors studied include critical, high, and medium; the drug classes studied for the purpose of this research are segmented as cephalosporins, beta-lactams, beta-lactamase inhibitors, oxazolidinone, cyclic lipopeptide, glycolipopeptides, and others. Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

The global multiple drug resistance bacterial infection treatment market is segmented geographically into North America, Europe, Asia Pacific, Latin America, and the Middle East and Africa markets.

The regions are also further sub-segmented on the basis of major countries:

  • North America
  • U.S.
  • Canada
  • Europe
  • U.K.
  • Germany
  • France
  • Rest of Europe
  • Asia-Pacific
  • China
  • Japan
  • India
  • Rest of Asia Pacific
  • Latin America
  • Mexico
  • Brazil
  • Rest of LATAM
  • Middle East and Africa
  • GCC
  • Rest of the Middle East and Africa

Market size estimates and forecasts for these segments are provided in US$ Mn, along with the respective CAGRs for the period 2017-2025, using 2016 as the base year.

This report also includes qualitative assessment factors such as market dynamics (drivers, restraints, and opportunities) to have a good understanding of the current and anticipated trends in the global multiple drug resistance bacterial infection treatment market. Competition assessment tools such as market attractiveness assessment and competitive landscape analysis by key players are also demonstrated in the study.

Furthermore, this report concludes with a profile of key market players currently enjoying prominent positions in the global multiple drug resistance bacterial infection treatment market. The key players profiled in this report are Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, and Zavante Therapeutics, Inc.

Based on drug class, the multiple drug-resistance bacterial infection treatment markets are categorized into

Cephalosporin

  • Cefixime (3rd Generation)
  • Ceftriaxone (3rd Generation)
  • Ceftobiprole (5th Generation)
  • Beta-Lactam
  • Doripenem
  • Imipenem
  • Meropenem
  • Ceftazidime
  • Beta-lactamase inhibitors
  • Sulbactam
  • Tazobactum
  • Avibactum
  • Clavam
  • Oxazolidinone
  • Linezolid
  • Cyclic Lipopeptide
  • Daptomycin
  • Glycolipopetides
  • Dalbavancin
  • Vancomycin

Others

  • Polymixins
  • Tetracycline and Derivatives
  • Penicillins
  • Macrolides
  • Macrolide-Lincosamide-Streptogramin
  • Rifamycins
  • Fluoroquinolones
  • Nitroimidazole
  • Potassium Bismuth Subcitrate

Antibiotic resistance is accelerated by the misuse and overuse of antibiotics, as well as poor infection prevention and control. According to World Health Organization (WHO) 2015 awareness guidelines, in order to prevent and control antibiotic resistance, use only the prescribed antibiotics, never share or use leftover antibiotics, and prevent infection by practicing safe sex, maintaining personal hygiene, consuming hygienic food and water, and staying up to date on vaccinations.

The factors responsible for the growth of the multiple drug resistance bacterial infection treatment market are the rising prevalence of antibiotic resistance and a promising pipeline to counteract existing drug resistance. Because of factors such as the rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa carbapenem resistance and the broad spectrum activity provided by beta-lactam drugs such as ceftazidime-avibactam and doripenem, beta-lactam drugs dominated the market in 2016.

Oxazolidinone and glycolipopeptides will be the fastest-growing segments throughout the forecast period of 2017–2025, primarily due to factors such as an increasing patient pool suffering from Enterococcus faecium and Staphylococcus aureus, methicillin and vancomycin resistance, and improved pharmacodynamic activity shown by drugs such as Linezolid and Dalbavancin.

Overall, the global multiple drug resistance bacterial infection treatment market is highly competitive with the presence of multiple players like Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc., Allergan plc, AstraZeneca, Bayer AG, Biocon, Daiichi Sankyo Company, GlaxoSmithKline plc, Macrolide Pharmaceuticals, Inc., Merck & Co., Inc., Pfizer, Inc., Sanofi, Teva Pharmaceuticals Industries Ltd., Wockhardt, Zavante Therapeutics, Inc., etc., Consolidation activities are being increasingly witnessed on the competitive front with a view to increasing the number of novel antibiotics to counteract drug resistance and improve pharmacokinetics for better patient compliance and low cost.

Based on vector, the global multiple drug resistance bacterial infection treatment market is categorized into

Critical

  • Acinetobacter baumannii (resistant to carbapenems)
  • Pseudomonas aeruginosa (resistant to carbapenem)
  • Carbapenem-resistant Enterobacteriaceae

High

  • Enterococcus faecium (Vancomycin-Resistant)
  • (Clarithromycin-Resistant) Helicobacter pylori
  • Staphylococcus aureus (methicillin-resistant, vancomycin-intermediate, and resistant)
  • Neisseria gonorrhea (Fluoroquinolone-Resistant, Cephalosporin-Resistant)

Medium

  • Streptococcus pneumonia (penicillin-non-Susceptible)
  • Haemophilus influenza (ampicillin-resistant)
  • Shigella spp. (fluoroquinolone-resistant)
  • Clostridium difficile (Cephalosporin-Resistant, Tetracycline-Resistant)

According to the Department of Health and Human Services Assistant Secretary for Preparedness and Response (ASPR) 2015 report, there have been 15 corporate entries and 36 corporate exits involved in antimicrobial treatment over the last 15 years. In 2016, the critical vector segment held the largest market in the multiple drug resistance bacterial infection treatment market, chiefly due to factors such as the rising prevalence of Enterobacteriaceae and Pseudomonas aeruginosa Carbapenem resistance cases and the lack of novel drug launches in the beta-lactam antibiotics.

This will serve as a great opportunity for budding industries to reclaim new grounds to fortify their product portfolio. The high segment will be the fastest growing market throughout the forecast period 2017-2025 due to the extensive growth in Helicobacter pylori (clarithromycin-resistant) and Staphylococcus aureus (methicillin-resistant, vancomycin-intermediate, and resistant) infections and the recent launch of novel drug formulations. Pylera is used to overcome clarithromycin resistance in peptic ulcer treatment; drugs such as linezolid, daptomycin, and dalbavancin have an effective mechanism of action in comparison to vancomycin in the treatment of antibiotic resistance.

In 2016, North America was identified as the largest market for multiple drug resistance bacterial infection treatment. According to the Department of Health and Human Services 2015 CDC report, approximately 23,000 Americans die each year due to antimicrobial drug resistance; the growth is attributed mainly to the rising prevalence of multiple drug resistance cases, evolved health infrastructure, and affordable reimbursement scenarios. According to the European Centre for Disease Prevention and Control, approximately 25,000 deaths were associated with multidrug-resistant bacterial infection; the growth is chiefly attributed to high public awareness regarding multiple drug resistance leading to early diagnosis and treatment and supportive regulatory approval for the launch of new antibiotics for the treatment of multiple drug resistance.

Asia Pacific will be the fastest-growing regional segment throughout the forecast period of 2017–2025. The growth is attributed to factors like the rising prevalence of geriatric populations suffering from multiple drug-resistant bacterial infections and increasing disposable income in these regions. Factors such as developing health infrastructure and increasing awareness regarding the judicious use of prescribed antibiotics, especially in remote areas, are going to fuel the rapid growth of the multiple drug resistance bacterial infection treatment market in Latin America, the Middle East, and Africa in the near future.

Frequently Asked Question:

The market for Multiple Drug Resistance Bacterial Infection Treatment Market is expected to reach USD$ 44,060.77 Mn in 2025.

The Multiple Drug Resistance Bacterial Infection Treatment Market is expected to see significant CAGR growth over the coming years, at 6.01 %.

The report is forecasted from 2017 -2025.

The base year of this report is 2016.

Abbott Laboratories, Inc., Actelion Pharmaceuticals Ltd., Albany Molecular Research, Inc. are some of the major players in the global market.

Choose License Type
Trusted By
Godaddy
Published Date:  Jul 2017
Category:  Pharmaceuticals
Report ID:   58597
Report Format:   PDF
Pages:   120
Rating:    4.7 (70)
Delivery Time: 24 Hours to 48 Hours   
Connect With Us
+91-8668442535
24/7 Research Support